Handa Pharmaceuticals, Inc. (TPEX: 6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
78.30
-3.50 (-4.28%)
Sep 10, 2024, 2:59 PM CST
-50.60%
Market Cap 11.05B
Revenue (ttm) 972.97M
Net Income (ttm) 452.32M
Shares Out 141.09M
EPS (ttm) 3.24
PE Ratio 24.15
Forward PE 4.90
Dividend 1.00 (1.22%)
Ex-Dividend Date Apr 18, 2024
Volume 527,246
Open 80.10
Previous Close 81.80
Day's Range 78.00 - 81.00
52-Week Range 66.70 - 206.00
Beta 1.43
Analysts n/a
Price Target n/a
Earnings Date Dec 26, 2024

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-0... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.